Clinical Pharmacokinetics of Atypical Antipsychotics: An Update

被引:130
作者
Mauri, Massimo Carlo [1 ]
Paletta, Silvia [1 ]
Di Pace, Chiara [1 ]
Reggiori, Alessandra [1 ]
Cirnigliaro, Giovanna [1 ]
Valli, Isabel [2 ]
Altamura, Alfredo Carlo [1 ]
机构
[1] Fdn IRCCS Ca Granda, Osped Maggiore Policlin, Dept Neurosci & Mental Hlth, Clin Psychopharmacol Unit,Clin Psychiat, Via F Sforza 35, I-20122 Milan, Italy
[2] Kings Coll London, Dept Psychosis Studies, London, England
关键词
OLANZAPINE PLASMA-CONCENTRATIONS; MULTIPLE-DOSE PHARMACOKINETICS; PERFORMANCE LIQUID-CHROMATOGRAPHY; PALIPERIDONE EXTENDED-RELEASE; ACTING INJECTABLE RISPERIDONE; DOPAMINE-D-2 RECEPTOR OCCUPANCY; LONG-TERM SAFETY; DOUBLE-BLIND; SCHIZOPHRENIC-PATIENTS; SERUM CONCENTRATIONS;
D O I
10.1007/s40262-018-0664-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Therapeutic drug monitoring studies have generally concentrated on controlling compliance and avoiding side effects by maintaining long-term exposure to minimally effective blood concentrations. The rationale for using therapeutic drug monitoring in relation to second-generation antipsychotics is still being discussed at least with regard to the real clinical utility, but there is evidence that it can improve efficacy, especially when patients do not respond or develop side effects using therapeutic doses. Furthermore, drug plasma concentration determinations can be of some utility in medico-legal problems. This review concentrates on the clinical pharmacokinetic data related to clozapine, risperidone, paliperidone, olanzapine, quetiapine, amisulpride, ziprasidone, aripiprazole, sertindole, asenapine, iloperidone, lurasidone, brexpiprazole and cariprazine and briefly considers the main aspects of their pharmacodynamics. Optimal plasma concentration ranges are proposed for clozapine, risperidone, paliperidone and olanzapine because the studies of quetiapine, amisulpride, asenapine, iloperidone and lurasidone provide only limited information and there is no direct evidence concerning ziprasidone, aripiprazole, sertindole, brexpiprazole and cariprazine: the few reported investigations need to be confirmed and extended.
引用
收藏
页码:1493 / 1528
页数:36
相关论文
共 277 条
[1]  
ACKENHEIL M, 1976, ARZNEIMITTEL-FORSCH, V26, P1156
[2]  
Actavis, 2015, CAR FULL PRESCR INF
[3]   Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations [J].
Aichhorn, W ;
Marksteiner, J ;
Walch, T ;
Zernig, G ;
Saria, A ;
Kemmler, G .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2006, 21 (02) :81-85
[4]   Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms [J].
Akamine, Yumiko ;
Sugawara-Kikuchi, Yuka ;
Uno, Tsukasa ;
Shimizu, Tetsuo ;
Miura, Masatomo .
ANNALS OF CLINICAL BIOCHEMISTRY, 2017, 54 (06) :677-685
[5]   Relationship Between Daily Dose, Serum Concentration, and Clinical Response to Quetiapine in Children and Adolescents with Psychotic and Mood Disorders [J].
Albantakis, Laura ;
Egberts, Karin ;
Burger, Rainer ;
Kulpok, Christine ;
Mehler-Wex, Claudia ;
Taurines, Regina ;
Unterecker, Stefan ;
Wewetzer, Christoph ;
Romanos, Marcel ;
Gerlach, Manfred .
PHARMACOPSYCHIATRY, 2017, 50 (06) :248-255
[6]   Zotepine loading in acute and severely manic patients:: a pilot study [J].
Amann, B ;
Sterr, A ;
Mergl, R ;
Dittmann, S ;
Seemüller, F ;
Dobmeier, M ;
Orth, M ;
Schaefer, M ;
Grunze, H .
BIPOLAR DISORDERS, 2005, 7 (05) :471-476
[7]  
Anderson Cheryl, 1994, Psychopharmacology Bulletin, V30, P88
[8]  
[Anonymous], 2015, SAPHRIS PRODUCT INFO
[9]   Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia [J].
Arakawa, Ryosuke ;
Ito, Hiroshi ;
Takano, Akihiro ;
Takahashi, Hidehiko ;
Morimoto, Takuya ;
Sassa, Takeshi ;
Ohta, Katsuya ;
Kato, Motoichiro ;
Okubo, Yoshiro ;
Suhara, Tetsuya .
PSYCHOPHARMACOLOGY, 2008, 197 (02) :229-235
[10]   Plasma level monitoring of olanzapine in patients with schizophrenia: Determination by high-performance liquid chromatography with electrochemical detection [J].
Aravagiri, M ;
Ames, D ;
Wirshing, WC ;
Marder, SR .
THERAPEUTIC DRUG MONITORING, 1997, 19 (03) :307-313